Cytarabine IT

Phase 1Small molecule

CC17 Council

Cytarabine IT is one of 47 small molecule programs targeting CNS Embryonal Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CNS Embryonal TumorRecruiting

Hematologic MalignanciesRecruiting

CNS Embryonal TumorPhase 1

Recruiting

Hematologic MalignanciesPhase 1

Recruiting

Competition

Competitive Landscape

53 competitors in Hematologic Malignancies

#DrugCompanyPhaseTrials

Avycaz

PPhiladelphia Eye Associates

Approved

1 2

Cellcept

Roche

Phase 2

22 3

Fludara

Sanofi

Phase 2

21 4

Cytoxan

BBaxter Healthcare Corporation

Phase 2

28 5

Cytosar

Teva

Phase 2

10 6

Atgam

Novartis

Phase 2

8 7

Trexall

Jazz Pharmaceuticals

Phase 2

7 8

Prograf

VVeloxis Pharmaceuticals

Phase 2

19 9

Alkeran

Adriamycin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Hematologic Malignancies

NCT05476770

Q4 2032

Phase 1Recruiting

CNS Embryonal Tumor

NCT06942039

Clinical

Trials by Indication[1]

Hematologic Malignancies1 trial

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Recruiting·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1·NCT05476770·54 enrolled

CNS Embryonal Tumor1 trial

A Pilot Study of Intrathecal Topotecan and Maintenance Chemotherapy in the Post-consolidation Setting for the Treatment of High-risk Embryonal Central Nervous System Tumours in Children Less Than 6 Years of Age

Recruiting·CC17 Council·Phase 1·NCT06942039·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Cytarabine IT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cytarabine IT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cytarabine IT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — C17 Council company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CC17 Council

Cytarabine IT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2032

Trials by Indication[1]

Hematologic Malignancies1 trial

CNS Embryonal Tumor1 trial

References

Drug Info

Quick Facts

Related News